Ligand Pharmaceuticals マネジメント
マネジメント 基準チェック /34
Ligand Pharmaceuticalsの CEO はTodd Davisで、 Dec2022年に任命され、 の在任期間は 1.92年です。 の年間総報酬は$ 6.22Mで、 10.5%給与と89.5%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.42%を直接所有しており、その価値は$ 9.44M 。経営陣と取締役会の平均在任期間はそれぞれ2年と15年です。
主要情報
Todd Davis
最高経営責任者
US$6.2m
報酬総額
| CEO給与比率 | 10.5% |
| CEO在任期間 | 1.9yrs |
| CEOの所有権 | 0.4% |
| 経営陣の平均在職期間 | 2yrs |
| 取締役会の平均在任期間 | 15yrs |
経営陣の近況
Recent updates
Ligand Pharmaceuticals: Buy This Strong Growing Pharma And Get A Stake In Dozens Of Therapies
Nov 24Market Participants Recognise Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Earnings
Oct 31
Ligand Pharmaceuticals: Solid Performer Performing Solidly
Jul 29Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Jul 18Should You Be Adding Ligand Pharmaceuticals (NASDAQ:LGND) To Your Watchlist Today?
Jun 29Subdued Growth No Barrier To Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) With Shares Advancing 27%
May 23Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio
Apr 30Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar
Dec 19Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?
Jun 14We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
May 29Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?
May 07These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well
Jan 26We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
Oct 21Ligand Pharmaceuticals: Struggling Along
Sep 25Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%
Aug 11Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly
Jun 27CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$45m |
| Jun 30 2024 | n/a | n/a | US$42m |
| Mar 31 2024 | n/a | n/a | US$96m |
| Dec 31 2023 | US$6m | US$650k | US$54m |
| Sep 30 2023 | n/a | n/a | US$21m |
| Jun 30 2023 | n/a | n/a | US$41m |
| Mar 31 2023 | n/a | n/a | US$51m |
| Dec 31 2022 | US$6m | US$49k | -US$5m |
| Sep 30 2022 | n/a | n/a | US$23m |
| Jun 30 2022 | n/a | n/a | US$27m |
| Mar 31 2022 | n/a | n/a | US$45m |
| Dec 31 2021 | US$328k | n/a | US$76m |
| Sep 30 2021 | n/a | n/a | US$68m |
| Jun 30 2021 | n/a | n/a | US$48m |
| Mar 31 2021 | n/a | n/a | US$39m |
| Dec 31 2020 | US$329k | n/a | US$7m |
| Sep 30 2020 | n/a | n/a | -US$16m |
| Jun 30 2020 | n/a | n/a | -US$25m |
| Mar 31 2020 | n/a | n/a | -US$61m |
| Dec 31 2019 | US$350k | n/a | US$629m |
| Sep 30 2019 | n/a | n/a | US$594m |
| Jun 30 2019 | n/a | n/a | US$677m |
| Mar 31 2019 | n/a | n/a | US$764m |
| Dec 31 2018 | US$343k | n/a | US$143m |
| Sep 30 2018 | n/a | n/a | US$179m |
| Jun 30 2018 | n/a | n/a | US$120m |
| Mar 31 2018 | n/a | n/a | US$53m |
| Dec 31 2017 | US$283k | n/a | US$13m |
報酬と市場: Toddの 総報酬 ($USD 6.22M ) は、 US市場 ($USD 5.50M ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Toddの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者
Todd Davis (63 yo)
1.9yrs
在職期間
US$6,216,518
報酬
Mr. Todd C. Davis, Ph.D. is a Director at NVN Liquidation Inc. He serves as an Independent Director of Channel Therapeutics Corporation (formerly known as Chromocell Therapeutics Corporation) since January...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 1.9yrs | US$6.22m | 0.42% $ 9.4m | |
| Chief Financial Officer | 2yrs | US$2.45m | 0.13% $ 2.9m | |
| Chief Legal Officer & Secretary | 2yrs | US$2.34m | 0.12% $ 2.7m | |
| Senior Vice President of Investments & Business Development | no data | データなし | データなし | |
| Head of Investor Relations | no data | データなし | データなし | |
| Director of Corporate Development | no data | データなし | データなし | |
| Senior Vice President of Biology & Scientific Affairs | 6.8yrs | データなし | データなし | |
| Senior Vice President of Technical Operations & QA - Capitsol | 6.8yrs | データなし | データなし | |
| Senior VP & CBO Protein Expression Business | no data | データなし | データなし | |
| Senior VP of Investments & Head of Clinical Strategy | less than a year | データなし | データなし | |
| Senior VP of Investment Operation | less than a year | データなし | データなし | |
| CEO of Pelthos Therapeutics | less than a year | データなし | データなし |
2.0yrs
平均在職期間
57yo
平均年齢
経験豊富な経営陣: LGNDの経営陣は 経験豊富 とはみなされません ( 2年の平均在職年数)。これは新しいチームを示唆しています。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 17.7yrs | US$6.22m | 0.42% $ 9.4m | |
| Independent Chairman | 21.7yrs | US$361.70k | 0.23% $ 5.1m | |
| Independent Director | 13.8yrs | US$329.20k | 0.15% $ 3.4m | |
| Independent Director | 16.3yrs | US$341.70k | 0.15% $ 3.4m | |
| Independent Director | 18.2yrs | US$339.20k | 0.43% $ 9.8m | |
| Scientific Advisor | no data | データなし | データなし | |
| Independent Director | 2.4yrs | US$346.70k | 0.022% $ 494.1k | |
| Independent Director | 7.3yrs | US$336.70k | 0.030% $ 671.4k | |
| Independent Director | 1.2yrs | US$467.87k | データなし |
15.0yrs
平均在職期間
63.5yo
平均年齢
経験豊富なボード: LGNDの 取締役会 は経験豊富で 経験豊富 です ( 15年の平均在任期間)。